NEW YORK (GenomeWeb) – Astute Medical said this week that it has signed an agreement with Shanghai Fosun Long March Medicine Science for distribution of its NephroCheck test for assessing risk of acute kidney injury in China.

The deal also calls for Fosun to provide Astute with $20 million in financing, which the company plans to use for ongoing commercialization of NephroCheck as well as development of additional tests in its pipeline, CEO Christopher Hibberd told GenomeWeb.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

Already a 360Dx Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.